CV
OXFD

Clarus Ventures’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Clarus Ventures’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-445,093
Closed -$6.89M – 6
2017
Q1 		$6.89M Sell
445,093
-714,332
-62% -$10.2M 5.13% 4
2016
Q4 		$17.3M Sell
1,159,425
-993,667
-46% -$13.9M 11.42% 3
2016
Q3 		$27M Hold
2,153,092
– – 16.62% 2
2016
Q2 		$19.4M Hold
2,153,092
– – 16.95% 2
2016
Q1 		$21.3M Hold
2,153,092
– – 16.02% 2
2015
Q4 		$24.8M Hold
2,153,092
– – 17.35% 2
2015
Q3 		$29.1M Sell
2,153,092
-14,285
-0.7% -$194K 16.72% 2
2015
Q2 		$30M Sell
2,167,377
-203,951
-9% -$2.76M 13.2% 4
2015
Q1 		$33.4M Sell
2,371,328
-207,734
-8% -$2.83M 13.88% 4
2014
Q4 		$35.1M Hold
2,579,062
– – 10.03% 5
2014
Q3 		$39.4M Hold
2,579,062
– – 15.71% 4
2014
Q2 		$43.4M Hold
2,579,062
– – 15.41% 4
2014
Q1 		$51.8M Hold
2,579,062
– – 14.98% 4
2013
Q4 		$50M Buy
+2,579,062
New +$45.6M 14.12% 4

Other funds holding OXFD

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Clarus Ventures's OXFD Position: Q2 2017 in Review

Clarus Ventures sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2017, closing a stake of 445,093 shares — an estimated $6.89M sold.

Clarus Ventures first reported a position in OXFD in Q4 2013 and held it in 14 quarters. The position peaked at $51.8M in Q1 2014. 75 funds tracked by Wall St. Rank hold OXFD as of Q2 2017.

  • Clarus Ventures reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Clarus Ventures sold 445,093 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2017, an estimated $6.89M.
  • Clarus Ventures first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2013 and held it in 14 quarters.
  • Clarus Ventures's Oxford Immunotec Global PLC Ordinary Shares position peaked at $51.8M in Q1 2014.
  • 75 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2017.

Based on Clarus Ventures's 13F filing for Q2 2017, filed 3 Aug 2017.